PTX-912

Phase 1Small molecule

PTX-912 is one of 4 small molecule programs targeting Locally Advanced/Metastatic Solid Tumors. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Locally Advanced/metastatic Solid TumorsRecruiting

Locally Advanced/metastatic Solid TumorsPhase 1

Recruiting

Competition

Competitive Landscape

9 competitors in Locally Advanced/metastatic Solid Tumors

#DrugCompanyPhaseTrials

Abraxane

Bristol-Myers Squibb

Phase 2

1 2

Cytoxan

BBaxter Healthcare Corporation

Phase 2

1 3

Anti-PD-1 Monoclonal Antibody

IiTeos Therapeutics

Phase 2

1 4

PTX-912

PProviva Therapeutics, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Locally Advanced/Metastatic Solid Tumors1 trial

A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors

Recruiting·PProviva Therapeutics, Inc.·Phase 1·NCT06190886·26 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for PTX-912. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PTX-912 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PTX-912. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Proviva Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: PProviva Therapeutics, Inc.

PTX-912

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Locally Advanced/Metastatic Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News